Pliant Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel integrin-based therapeutics. Following the strategic discontinuation of its lead candidate bexotegrast for idiopathic pulmonary fibrosis (IPF) in 2025 due to an unfavorable risk-benefit profile, the company has pivoted its primary focus to its oncology pipeline. Its current lead clinical candidate is PLN-101095, an oral, small molecule, dual-selective inhibitor of ́v̈8 and ́v̈1 integrins. PLN-101095 is designed to block TGF-́̂ activation in the tumor microenvironment, thereby overcoming immune checkpoint inhibitor (ICI) resistance. The company is currently evaluating PLN-101095 in the FORTIFY Phase 1b indication expansion trial for patients with ICI-refractory advanced or metastatic solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the discontinuation of the lead bexotegrast program in IPF in 2025, Pliant has pivoted its strategic focus toward its oncology pipeline, specifically advancing PLN-101095, an oral dual-selective inhibitor of avB8 and avB1 integrins.
Expected impact: Aims to establish PLN-101095 as a novel immuno-oncology approach for immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.
Implemented a strategic restructuring of its workforce (cutting approximately 45% of staff in 2025) and other cost-saving actions to minimize operating expenses and extend the cash runway.
Expected impact: Significantly lowered quarterly net losses (reduced to $20.0 million in Q1 2026 from $56.2 million in Q1 2025) and extended the cash runway into the second half of 2028.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
In response to Tang Capital Partners accumulating a 9.6% stake in Pliant and the threat of a hostile cash + CVR acquisition bid, Pliant adopted a shareholder rights plan ('poison pill') in March 2025 to protect against unsolicited takeovers.
Terms: The rights plan triggers if an entity acquires 10% or more of Pliant's common stock.